IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Relapsed Solid Tumor
Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Relapsed Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sidnei Epelman | Phase 2 | CCC |
Abemaciclib Eli Lilly and Company | Phase 1/2 | CCC |
Irinotecan Eli Lilly and Company | Phase 1/2 | CCC |
Gm-Csf Eli Lilly and Company | Phase 1/2 | CCC |
Dinutuximab Eli Lilly and Company | Phase 1/2 | CCC |
IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN MONOCLONAL STI-3031 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL STI-3031 .LAMBDA.-CHAIN, DIMER Sorrento Therapeutics, Inc. | Phase 2 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →